FDA Warns Chinese Firm for Testing, Validation Failures

Drug Industry Daily
A A
The FDA issued a warning letter to a Chinese drugmaker for significant cGMP violations related to identity testing, process validation and its written stability program.

To View This Article:

Login

Subscribe To Drug Industry Daily